v3.26.3
Segment Information - Summary of Financial Data for Development of Pharmaceutical Products Segments (Details) - USD ($)
 12 Months Ended
Jun. 30, 2026
Jun. 30, 2025
Jun. 30, 2024
Operating and other (income) expense      
Employee expenses $ 2,166,000 $ 9,293,000  
Other segment expenses 3,578,000 [1] 2,647,000 [2]  
Professional fees 2,264,000 2,754,000  
Legal fees 1,581,000 1,723,000  
Asset management fee and advisory fees 2,521,000    
Change in fair value of digital assets 54,408,000 0  
Change in fair value of digital assets receivable, net 5,653,000 0  
Gain on derivative liabilities, net (813,000) 0  
Gain on disposition of a nonfinancial asset 0 (500,000)  
Interest and dividend income (267,000) [3] (1,026,000) [4]  
Total operating and other (income) expense 71,150,000 15,945,000  
Net loss (71,150,000) (15,945,000) $ 18,000,000
Current assets:      
Cash and cash equivalents 5,706,000 18,011,000  
Prepaid expenses and other current assets 435,000 274,000  
Total current assets 6,141,000 18,285,000  
Digital assets 27,272,000 0  
Digital assets receivable, net 7,627,000    
Investment in SAFE and Token Warrants 1,000,000 0  
Other long-term assets 652,000 0  
Total assets 42,692,000 18,285,000  
voruciclib      
Operating and other (income) expense      
Other segment expenses 59,000 801,000  
ME-344      
Operating and other (income) expense      
Other segment expenses   253,000  
Operating Segments [Member]      
Operating and other (income) expense      
Employee expenses 856,000    
Other segment expenses [1] 86,000    
Professional fees 720,000    
Legal fees 741,000    
Asset management fee and advisory fees 2,521,000    
Change in fair value of digital assets 54,408,000    
Change in fair value of digital assets receivable, net 5,653,000    
Gain on derivative liabilities, net (813,000)    
Interest and dividend income [3] 0    
Total operating and other (income) expense 64,231,000    
Net loss (64,231,000)    
Current assets:      
Cash and cash equivalents 0    
Prepaid expenses and other current assets 159,000    
Total current assets 159,000    
Digital assets 27,272,000    
Digital assets receivable, net 7,627,000    
Investment in SAFE and Token Warrants 1,000,000    
Other long-term assets 0    
Total assets 36,058,000    
Operating Segments [Member] | Digital Asset Treasury Strategy      
Operating and other (income) expense      
Employee expenses 811,000    
Other segment expenses [1] 70,000    
Professional fees 718,000    
Legal fees 112,000    
Asset management fee and advisory fees 2,521,000    
Change in fair value of digital assets 54,408,000    
Change in fair value of digital assets receivable, net 5,653,000    
Gain on derivative liabilities, net (813,000)    
Interest and dividend income [3] 0    
Total operating and other (income) expense 63,480,000    
Net loss (63,480,000)    
Current assets:      
Cash and cash equivalents 0    
Prepaid expenses and other current assets 128,000    
Total current assets 128,000    
Digital assets 27,272,000    
Digital assets receivable, net 7,627,000    
Investment in SAFE and Token Warrants 1,000,000    
Other long-term assets 0    
Total assets 36,027,000    
Operating Segments [Member] | Development of Pharmaceutical Products      
Operating and other (income) expense      
Employee expenses 45,000 2,602,000  
Other segment expenses 16,000 [1] 242,000 [2]  
Professional fees 2,000 25,000  
Legal fees 629,000 602,000  
Asset management fee and advisory fees 0    
Change in fair value of digital assets 0    
Change in fair value of digital assets receivable, net 0    
Gain on derivative liabilities, net 0    
Gain on disposition of a nonfinancial asset   0  
Interest and dividend income 0 [3] 0 [4]  
Total operating and other (income) expense 751,000 4,525,000  
Net loss (751,000) (4,525,000)  
Current assets:      
Cash and cash equivalents 0 0  
Prepaid expenses and other current assets 31,000 25,000  
Total current assets 31,000 25,000  
Digital assets 0    
Digital assets receivable, net 0    
Investment in SAFE and Token Warrants 0    
Other long-term assets 0    
Total assets 31,000 25,000  
Operating Segments [Member] | voruciclib      
Operating and other (income) expense      
Other segment expenses 59,000    
Operating Segments [Member] | voruciclib | Digital Asset Treasury Strategy      
Operating and other (income) expense      
Other segment expenses 0    
Operating Segments [Member] | voruciclib | Development of Pharmaceutical Products      
Operating and other (income) expense      
Other segment expenses 59,000 801,000  
Operating Segments [Member] | ME-344 | Development of Pharmaceutical Products      
Operating and other (income) expense      
Other segment expenses   253,000  
Corporate [Member]      
Operating and other (income) expense      
Employee expenses 1,310,000 6,691,000  
Other segment expenses 3,492,000 [1] 2,405,000 [2]  
Professional fees 1,544,000 2,729,000  
Legal fees 840,000 1,121,000  
Asset management fee and advisory fees 0    
Change in fair value of digital assets 0    
Change in fair value of digital assets receivable, net 0    
Gain on derivative liabilities, net 0    
Gain on disposition of a nonfinancial asset   (500,000)  
Interest and dividend income (267,000) [3] (1,026,000) [4]  
Total operating and other (income) expense 6,919,000 11,420,000  
Net loss (6,919,000) (11,420,000)  
Current assets:      
Cash and cash equivalents 5,706,000 18,011,000  
Prepaid expenses and other current assets 276,000 249,000  
Total current assets 5,982,000 18,260,000  
Digital assets 0    
Digital assets receivable, net 0    
Investment in SAFE and Token Warrants 0    
Other long-term assets 652,000    
Total assets 6,634,000 18,260,000  
Corporate [Member] | voruciclib      
Operating and other (income) expense      
Other segment expenses $ 0 0  
Corporate [Member] | ME-344      
Operating and other (income) expense      
Other segment expenses   $ 0  
[1]

(1) Includes product development costs associated with zandelisib determined to be immaterial, share-based compensation costs, administrative costs, travel and business taxes.
[2]

(1) Includes product development costs associated with zandelisib determined to be immaterial, occupancy costs (including rent and utilities), share-based compensation costs, depreciation expense, administrative costs, travel and business taxes.
[3]

(2) Interest and dividend income are solely attributable to our cash and cash equivalents.
[4]

(2) Interest and dividend income are solely attributable to our cash and cash equivalents.